Education
About Us
Working with TipRanks
Follow Us
Jonathan Lieber Insider Profile
4 Followers
Jonathan Lieber, CFO at Ocugen, holds 4.12K shares in Rallybio (Ticker: RLYB), holds 2.94K shares in Decoy Therapeutics (Ticker: DCOY), holds 0.00 shares in Ocugen (Ticker: OCGN).
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-57.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jonathan Lieber holds in companies
Most Profitable Insider Trade
The most profitable trade made by Jonathan Lieber
Jonathan Lieber's Trading History
Ocugen
Dec 02, 2016
CFO
Informative Buy
9.70K
$0.00
Decoy Therapeutics
Jan 05, 2023
Director
Uninformative Buy
―
$22.40K
Applied Genetic Technologies
―
―
―
―
Rallybio
Feb 23, 2026
CFO
Uninformative Buy
―
$39.09K
Repligen
Sep 24, 2012
CFO
Uninformative Buy
―
$1.71M
List of latest transactions for each holding click on a transaction to see Jonathan Lieber's performance on stock
You May Also Like
Jonathan Lieber insider profile FAQ
What is the percentage of profitable transactions made by Jonathan Lieber?
The percentage of profitable transactions made by Jonathan Lieber is 25%.
What is the average return per transaction made by Jonathan Lieber?
The average return per transaction made by Jonathan Lieber is -57.10%.
What stocks does Jonathan Lieber hold?
Jonathan Lieber holds: OCGN, DCOY, AGTC, RLYB, RGEN stocks.
What was Jonathan Lieber’s latest transaction?
Jonathan Lieber latest transaction was an Uninformative Buy of ―.
What was Jonathan Lieber's most profitable transaction?
Jonathan Lieber’s most profitable transaction was an Informative Buy of OCGN stock on December 2, 2016. The return on the trade was 2.00%.
What is Jonathan Lieber's role in Ocugen?
Jonathan Lieber's role in Ocugen is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.